ARS Pharmaceuticals Snags $55M In Series D Funding
socalTECH
AUGUST 31, 2021
San Diego-based "ARS Pharmaceuticals, which is developing an epinephrine nasal spray designed to better treat severe allergic reaction, said today that it has raised $55M in a Series D funding. The funding was led by SR One, and also included RA Capital Management, an un-named US healthcare-focused fund, and Deerfield Management.
Let's personalize your content